Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Psyched Wellness is investigating how the food supplement AME-1 extract could modify microglial functions
  • The company says this could “potentially indicate that AME-1 boosts the antiviral immune response in the brain”
  • Preliminary data from tests have been completed by the National Research Council of Canada
  • The company is also launching its first AME-1 product, Calm, in the coming months
  • Psyched Wellness is a life sciences company focused on the production and distribution of health & wellness products derived from the Amanita Muscaria mushroom
  • Psyched Wellness Ltd. (PSYC) is up 11.11 per cent trading at C$0.15 as of 10:40 am EDT

Psyched Wellness (PSYC) has announced preliminary data from tests completed by the National Research Council of Canada (NRC).

Recent work investigated how the food supplement AME-1 extract could modify microglial functions.

One of the primary immune cells in the brain are the microglia, which facilitate neurodevelopment and neurodegeneration.

Microglia respond to a variety of stimuli, including lipopolysaccharides found in the cell walls of bacteria (LPS), viral components (such as poly I:C nucleotides), and inflammatory cytokines such as tumour necrosis factor (TNF).

In a recent study, researchers stimulated human microglial cells with LPS, poly I:C, and TNF in the presence of AME-1 to determine if AME-1 could modify how microglia respond to these common stimulants.

The researchers found that a specific nucleotide, poly I:C, caused the microglia to be more activated than normal and produce important immune mediators.

The company says this could potentially indicate that AME-1 boosts the antiviral immune response in the brain, perhaps protecting brain tissue from viral infection.

This work is preliminary, and more work is needed to further investigate the potential benefits of the natural product AME-1.

Brian Tancowny, scientific advisor to Psyched Wellness, commented,

“This additional preliminary evidence of the investigative study is revealing key functional properties of the AME-1 extract. These Amanita Muscaria mushroom functional properties will be further investigated and identified in this scientific approach to help understand the functional neuroprotective property of AME-1.”

Company’s COO David Shisel added,

“When it comes to the Amanita Muscaria mushroom, we are the first in many fields of research,” “Our extract, AME-1 provides us with the opportunity to do multiple studies and the more we examine the extract, the more we understand this incredible powerful mushroom. This is just the tip of the iceberg and we plan to continue researching and understanding its powers along the way.”

Psyched Wellness is launching its first AME-1 product, Calm, in the coming months.

Psyched Wellness Ltd. (PSYC) is up 11.11 per cent trading at C$0.15 as of 10:40 am EDT.


More From The Market Herald

" Lobe Sciences (CSE: LOBE) update psilocin compounds and development plans on site

Lobe Sciences (LOBE) is updating its corporate presentation describing plans for advancing the development of its psilocin analogues L-130 and L-131.
PharmaDrug - CEO, Daniel Cohen

" PharmaDrug (CSE:PHRX) completes milestone to support cGMP production of PD-001

PharmaDrug (PHRX) has laid the groundwork to support cGMP production of cepharanthine-2HCL for use in the drug product production of PD-001.
Small Pharma - CEO, George Tziras.

" Small Pharma (TSXV:DMT) announces NCIB

Small Pharma (DMT) has received TSXV approval for a normal course issuer bid.